Matches in Wikidata for { <http://www.wikidata.org/entity/Q37363925> ?p ?o ?g. }
- Q37363925 description "2016 թվականի հոկտեմբերի 11-ին հրատարակված գիտական հոդված" @default.
- Q37363925 description "article científic" @default.
- Q37363925 description "article scientifique" @default.
- Q37363925 description "articolo scientifico" @default.
- Q37363925 description "artigo científico" @default.
- Q37363925 description "artículu científicu espublizáu en 2016" @default.
- Q37363925 description "bilimsel makale" @default.
- Q37363925 description "scientific article published on 11 October 2016" @default.
- Q37363925 description "vedecký článok" @default.
- Q37363925 description "vetenskaplig artikel" @default.
- Q37363925 description "videnskabelig artikel" @default.
- Q37363925 description "vědecký článek" @default.
- Q37363925 description "wetenschappelijk artikel" @default.
- Q37363925 description "wissenschaftlicher Artikel" @default.
- Q37363925 description "наукова стаття, опублікована в жовтні 2016" @default.
- Q37363925 description "научни чланак" @default.
- Q37363925 description "مقالة علمية نشرت في 11 أكتوبر 2016" @default.
- Q37363925 name "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 name "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 name "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 type Item @default.
- Q37363925 label "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 label "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 label "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 prefLabel "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 prefLabel "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 prefLabel "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature." @default.
- Q37363925 P1433 Q37363925-DAFC4C43-CD00-4E77-856F-D4C6AD04721B @default.
- Q37363925 P1476 Q37363925-772DCE25-4A96-463A-83EF-070628AC6EC2 @default.
- Q37363925 P2093 Q37363925-089A41FC-1F66-4672-B896-3097FCEC1C3A @default.
- Q37363925 P2093 Q37363925-46F59B71-E557-4A06-B24D-FD3BE681A012 @default.
- Q37363925 P2093 Q37363925-48619108-4367-463F-959F-B07DD97C6E55 @default.
- Q37363925 P2093 Q37363925-C116E348-8BFD-4016-B9D2-5E56E6D636A1 @default.
- Q37363925 P2093 Q37363925-CA201DE1-AD36-40A5-9BBB-AA8F74DDBDA0 @default.
- Q37363925 P275 Q37363925-D321553D-525D-4F1B-BE1E-AF128AA4C7F3 @default.
- Q37363925 P2860 Q37363925-0A33059B-4B27-4778-8F97-59D32C99AACC @default.
- Q37363925 P2860 Q37363925-0AED98FF-3829-44EA-B117-54802BA1C554 @default.
- Q37363925 P2860 Q37363925-0E02F027-1A90-44CA-9546-AD14828FFA46 @default.
- Q37363925 P2860 Q37363925-0EFBCDBA-95C8-4350-89AC-066F8C602C1F @default.
- Q37363925 P2860 Q37363925-0F4F90C5-CF89-4883-B759-E3528C9641E1 @default.
- Q37363925 P2860 Q37363925-0F8D686F-B535-42BB-898F-3D3230ABF751 @default.
- Q37363925 P2860 Q37363925-13FCEB66-DE62-4FE4-8471-EB8FF6D5F942 @default.
- Q37363925 P2860 Q37363925-14E8E715-019F-45CF-A71E-7207BD4D52F9 @default.
- Q37363925 P2860 Q37363925-1D7B9035-C1CC-4371-AEA9-2ECF11EAFA90 @default.
- Q37363925 P2860 Q37363925-230CDE95-4719-4680-9021-9CB23D1EF40D @default.
- Q37363925 P2860 Q37363925-2924E16A-0C2D-473C-B1D5-9074BA16D06C @default.
- Q37363925 P2860 Q37363925-33C2A97A-6D10-45A7-9D47-4637EB2A780C @default.
- Q37363925 P2860 Q37363925-39082F2E-1D2A-41B5-A8F9-6D17FB5F3A48 @default.
- Q37363925 P2860 Q37363925-7366D2F9-A749-4FF8-979D-811BD2A3BC11 @default.
- Q37363925 P2860 Q37363925-759EB348-7B52-4366-98EB-47F7712F567B @default.
- Q37363925 P2860 Q37363925-78B136D1-7515-4780-AC40-891201406CA5 @default.
- Q37363925 P2860 Q37363925-79E21965-04FC-4F98-868B-2B699D6C3F12 @default.
- Q37363925 P2860 Q37363925-7CEC246F-0616-45F6-B28A-0596BBF972EB @default.
- Q37363925 P2860 Q37363925-88D7ECD7-8555-4B50-B729-3C970C4C0DC4 @default.
- Q37363925 P2860 Q37363925-8F859818-8697-44EE-987E-1543C688AB31 @default.
- Q37363925 P2860 Q37363925-BB626A73-EC5C-49D4-859B-0EE86F7DC678 @default.
- Q37363925 P2860 Q37363925-C80009EA-A7F1-4047-9C7E-6CD73B0D0F6A @default.
- Q37363925 P2860 Q37363925-E96E4264-ECFF-42E9-92C7-7DEFA38B7794 @default.
- Q37363925 P2860 Q37363925-EDA56D41-2BF2-4A82-99D3-9B27A2724E09 @default.
- Q37363925 P304 Q37363925-77755915-2DF7-48F9-9A7A-974B1BBA016D @default.
- Q37363925 P31 Q37363925-F84F25ED-6C12-4BDE-9FC5-037454A84356 @default.
- Q37363925 P356 Q37363925-71FB218D-9870-4039-848D-07E225ED2CE1 @default.
- Q37363925 P478 Q37363925-A26F8FC2-7DF1-41D5-A2B3-3608D9C1ED95 @default.
- Q37363925 P50 Q37363925-0926DC9E-0FA5-4ECF-AEEA-088ECA86FD38 @default.
- Q37363925 P50 Q37363925-A28A89F5-F407-4573-9EE5-72329A922281 @default.
- Q37363925 P577 Q37363925-4E7B1EBB-2353-49C2-87FA-F911EE69944F @default.
- Q37363925 P6216 Q37363925-78D0F0FB-6AAA-4F8C-BAF9-DF6CC33A6749 @default.
- Q37363925 P698 Q37363925-3B7398CF-C68A-4022-ABD5-18CD3EF732F1 @default.
- Q37363925 P921 Q37363925-34140FC4-110D-428F-B642-910F30A6FC67 @default.
- Q37363925 P932 Q37363925-0B933F2C-28C4-45A6-8E4E-4E4A1E065221 @default.
- Q37363925 P356 2596423 @default.
- Q37363925 P698 27807492 @default.
- Q37363925 P1433 Q26842352 @default.
- Q37363925 P1476 "Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature" @default.
- Q37363925 P2093 "Alexander Brown" @default.
- Q37363925 P2093 "Arash Hassantoufighi" @default.
- Q37363925 P2093 "Dale Selby" @default.
- Q37363925 P2093 "Robert Setlik" @default.
- Q37363925 P2093 "Shyam Daya" @default.
- Q37363925 P275 Q20007257 @default.
- Q37363925 P2860 Q27304386 @default.
- Q37363925 P2860 Q33163524 @default.
- Q37363925 P2860 Q33338666 @default.
- Q37363925 P2860 Q33401346 @default.
- Q37363925 P2860 Q33817711 @default.
- Q37363925 P2860 Q34288599 @default.
- Q37363925 P2860 Q34621900 @default.
- Q37363925 P2860 Q36822162 @default.
- Q37363925 P2860 Q36862405 @default.
- Q37363925 P2860 Q37178611 @default.
- Q37363925 P2860 Q37384289 @default.
- Q37363925 P2860 Q37715109 @default.
- Q37363925 P2860 Q38386440 @default.
- Q37363925 P2860 Q40885119 @default.
- Q37363925 P2860 Q42957470 @default.
- Q37363925 P2860 Q46988370 @default.
- Q37363925 P2860 Q51779692 @default.
- Q37363925 P2860 Q52320721 @default.
- Q37363925 P2860 Q53648839 @default.
- Q37363925 P2860 Q73399572 @default.